VolitionRx Ltd., a multi-national epigenetics company, announced the presentation of two abstracts at the North America Conference on Lung Cancer (NACLC) in Chicago. The studies highlighted the use of Volition's Nu.Q® Cancer assays in the management of lung cancer patients. Results from these studies were presented at the conference. One study demonstrated that Nu.Q® Cancer assays, particularly the measurement of circulating H3K27Me3-nucleosomes, can support clinicians in treatment selection and patient monitoring, potentially improving prognostic accuracy and informing personalized care strategies. Another study found that pre-operative measurement of H3K27Me3-nucleosomes through a blood test may help stratify risk in Non Small Cell Lung Cancer patients, particularly in identifying those who may benefit from closer follow-up or additional treatment. The research indicates that Nu.Q®-H3K27Me3 levels correlate with cancer stage and could serve as an independent prognostic biomarker for overall survival. VolitionRx Ltd. reports ongoing efforts to introduce the Nu.Q® Cancer assays into routine clinical practice.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN41289) on December 08, 2025, and is solely responsible for the information contained therein.
Comments